MA37829A1 - Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha - Google Patents

Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Info

Publication number
MA37829A1
MA37829A1 MA37829A MA37829A MA37829A1 MA 37829 A1 MA37829 A1 MA 37829A1 MA 37829 A MA37829 A MA 37829A MA 37829 A MA37829 A MA 37829A MA 37829 A1 MA37829 A1 MA 37829A1
Authority
MA
Morocco
Prior art keywords
inhibitor
egfr
optionally
raf
pharmaceutical combinations
Prior art date
Application number
MA37829A
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37829A1 publication Critical patent/MA37829A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une combinaison pharmaceutique comprenant (a) un inhibiteur de b-raf, (b) un inhibiteur d'egfr et facultativement (c) un inhibiteur de pi3k ; les utilisations d'une telle combinaison dans le traitement de maladies de prolifération ; et des méthodes de traitement d'un sujet souffrant d'une maladie de prolifération comprenant l'administration d'une quantité thérapeutiquement efficace d'une telle combinaison.
MA37829A 2012-08-07 2015-02-04 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha MA37829A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (fr) 2012-08-07 2013-08-05 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Publications (1)

Publication Number Publication Date
MA37829A1 true MA37829A1 (fr) 2017-01-31

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37829A MA37829A1 (fr) 2012-08-07 2015-02-04 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Country Status (39)

Country Link
US (1) US9474754B2 (fr)
EP (2) EP3574904A1 (fr)
JP (3) JP6342396B2 (fr)
KR (1) KR102112885B1 (fr)
CN (1) CN104519887B (fr)
AR (1) AR092045A1 (fr)
AU (1) AU2013299841B8 (fr)
CA (1) CA2879548C (fr)
CL (1) CL2015000294A1 (fr)
CO (1) CO7200273A2 (fr)
CY (1) CY1122143T1 (fr)
DK (1) DK2882440T3 (fr)
EA (1) EA028420B1 (fr)
EC (1) ECSP15008695A (fr)
ES (1) ES2717911T3 (fr)
GT (1) GT201500025A (fr)
HK (2) HK1204976A1 (fr)
HR (1) HRP20190537T1 (fr)
HU (1) HUE042877T2 (fr)
IL (1) IL236934B (fr)
IN (1) IN2015DN00450A (fr)
JO (1) JOP20130236B1 (fr)
LT (1) LT2882440T (fr)
MA (1) MA37829A1 (fr)
MX (1) MX359403B (fr)
MY (1) MY176031A (fr)
NZ (1) NZ703940A (fr)
PE (2) PE20191655A1 (fr)
PH (1) PH12015500246A1 (fr)
PL (1) PL2882440T3 (fr)
PT (1) PT2882440T (fr)
RS (1) RS58734B1 (fr)
SG (1) SG11201500321YA (fr)
SI (1) SI2882440T1 (fr)
TN (1) TN2015000027A1 (fr)
TR (1) TR201904980T4 (fr)
TW (1) TWI607754B (fr)
UA (1) UA115786C2 (fr)
WO (1) WO2014025688A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092045A1 (es) * 2012-08-07 2015-03-18 Novartis Ag Combinaciones farmaceuticas
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
EA201790019A1 (ru) * 2014-06-16 2017-06-30 Уорлдуайд Иновейтив Нетуорк Способ выбора персонализированной трехкомпонентной терапии для лечения рака
WO2016193955A1 (fr) * 2015-06-04 2016-12-08 Giorgio Stassi Combinaisons d'inhibiteurs de kinase pour le traitement du cancer colorectal
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
US10328065B2 (en) 2015-08-28 2019-06-25 Novartis Ag Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
WO2017066664A1 (fr) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Polythérapie comprenant un inhibiteur de raf pour le traitement du cancer colorectal
EP3463345B1 (fr) 2016-06-03 2022-11-02 Array BioPharma Inc. Combinaisons pharmaceutiques
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
JP7309614B2 (ja) 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
BR112020001916A2 (pt) * 2017-08-03 2020-07-28 Novartis Ag combinação terapêutica de um inibidor de tirosina quinase de egfr de terceira geração e um inibidor de raf
PL3860998T3 (pl) 2018-10-05 2024-06-17 Annapurna Bio Inc. Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj
KR20210120039A (ko) * 2019-01-25 2021-10-06 베이진 엘티디 B-raf 키나제 이합체 억제제의 안정적인 고체 분산액, 이의 제조 방법 및 용도
WO2020164997A1 (fr) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
WO2023145530A1 (fr) * 2022-01-27 2023-08-03 国立大学法人東北大学 Agent thérapeutique contre le cancer
WO2023230554A1 (fr) 2022-05-25 2023-11-30 Pfizer Inc. Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
WO2024073364A1 (fr) * 2022-09-26 2024-04-04 Beigene, Ltd. Associations d'un inhibiteur de b-raf et d'un anticorps anti-egfr pour le traitement du cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2139484B9 (fr) 2007-04-10 2014-06-11 Exelixis, Inc. Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
SG10201402917XA (en) 2009-08-24 2014-08-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
KR20120097496A (ko) * 2009-10-12 2012-09-04 글락소스미스클라인 엘엘씨 조합물
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
AU2011328227B2 (en) * 2010-11-08 2015-04-09 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
WO2013070998A1 (fr) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center Traitement du cancer de l'ovaire par des 2-amino-4h-naphto[1,2-b]pyran-3-carbonitriles
JP6150813B2 (ja) * 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
AR092045A1 (es) * 2012-08-07 2015-03-18 Novartis Ag Combinaciones farmaceuticas

Also Published As

Publication number Publication date
PE20150673A1 (es) 2015-05-20
GT201500025A (es) 2017-09-28
PL2882440T3 (pl) 2019-07-31
TW201410247A (zh) 2014-03-16
AU2013299841A1 (en) 2015-02-12
WO2014025688A1 (fr) 2014-02-13
CY1122143T1 (el) 2020-11-25
CA2879548C (fr) 2020-07-21
KR20150040905A (ko) 2015-04-15
SI2882440T1 (sl) 2019-05-31
CA2879548A1 (fr) 2014-02-13
EP3574904A1 (fr) 2019-12-04
JP6595024B2 (ja) 2019-10-23
JP6974669B2 (ja) 2021-12-01
TR201904980T4 (tr) 2019-05-21
BR112015002384A2 (pt) 2017-07-04
CN104519887B (zh) 2017-06-27
US9474754B2 (en) 2016-10-25
JP6342396B2 (ja) 2018-06-13
ECSP15008695A (es) 2019-03-29
BR112015002384A8 (pt) 2019-07-30
CL2015000294A1 (es) 2015-05-08
LT2882440T (lt) 2019-04-25
TN2015000027A1 (en) 2016-06-29
EP2882440A1 (fr) 2015-06-17
MY176031A (en) 2020-07-22
PT2882440T (pt) 2019-04-23
IN2015DN00450A (fr) 2015-06-26
PH12015500246B1 (en) 2015-03-30
AU2013299841B8 (en) 2017-01-05
SG11201500321YA (en) 2015-04-29
ES2717911T3 (es) 2019-06-26
JP2018109022A (ja) 2018-07-12
JOP20130236B1 (ar) 2021-08-17
EA201590332A1 (ru) 2015-06-30
AU2013299841A8 (en) 2017-01-05
RS58734B1 (sr) 2019-06-28
UA115786C2 (uk) 2017-12-26
AR092045A1 (es) 2015-03-18
CN104519887A (zh) 2015-04-15
EP2882440B1 (fr) 2019-02-27
HK1211831A1 (en) 2016-06-03
JP2015524472A (ja) 2015-08-24
EA028420B1 (ru) 2017-11-30
MX359403B (es) 2018-09-26
PE20191655A1 (es) 2019-11-07
AU2013299841B2 (en) 2016-11-24
PH12015500246A1 (en) 2015-03-30
MX2015001732A (es) 2015-06-03
US20150265616A1 (en) 2015-09-24
NZ703940A (en) 2018-04-27
JP2020019780A (ja) 2020-02-06
HUE042877T2 (hu) 2019-07-29
KR102112885B1 (ko) 2020-05-19
DK2882440T3 (da) 2019-05-06
IL236934B (en) 2018-11-29
CO7200273A2 (es) 2015-02-27
HK1204976A1 (en) 2015-12-11
HRP20190537T1 (hr) 2019-06-28
TWI607754B (zh) 2017-12-11

Similar Documents

Publication Publication Date Title
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA033448B1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201000990A1 (ru) Лечение дисменореи путем трансдермального введения нестероидных противовоспалительных лекарственных средств
EA201200443A1 (ru) Комбинированное лекарственное средство и способ лечения венозных церебральных дисциркуляций
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA35927B1 (fr) Polythérapie pour le traitement d'un cancer de l'ovaire
MA38056A1 (fr) Inhibiteurs de la tyrosine kinase de bruton